You are here

Phase 3 Study of Tiagabine in Generalized Anxiety Disorder Fails to Reach Primary Endpoints

FRAZER, Pa., June 26 /PRNewswire-FirstCall/ -- Cephalon, Inc. (NASDAQ:CEPH) announced today that data from its Phase III clinical program evaluating GABITRIL(R) (tiagabine hydrochloride) for the treatment of generalized anxiety disorder (GAD) did not reach statistical significance on the primary study endpoints.

Cephalon will conduct a complete analysis of the data to assist in its evaluation of future clinical development plans for GABITRIL in other therapeutic areas.

Current Indication for GABITRIL
Cephalon currently markets GABITRIL in the United States and Europe. GABITRIL is indicated as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures. In three multicenter, double-blind, placebo-controlled, parallel-group clinical trials and two placebo-controlled crossover studies, GABITRIL significantly reduced the frequency of seizures in patients with epilepsy who took GABITRIL as add-on therapy. In epilepsy patients, dosing with GABITRIL is initiated at 4 mg dosed 2-4 times a day with food and titrated to a maintenance dose of 32-56mg/day in patients receiving hepatic enzyme-inducing anticonvulsants. The maximum dose in epilepsy patients is 32 mg in children and 56 mg in adults.

In clinical trials, GABITRIL was well tolerated with the most common adverse events being mild to moderate in severity. The most common adverse events were dizziness, asthenia (weakness), somnolence, nausea, nervousness, tremor, abdominal pain, and impaired concentration.

Source: Cephalon

Recent Headlines

Changes in Antibiotic Recommendations for Children
Influences Gene Involved in Circadian Rhythms
‘The Perfect Drug for Trauma-Focused Psychotherapy’
Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients